Oligometastatic Disease Clinical Trial
Official title:
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
NCT number | NCT06299852 |
Other study ID # | TK01 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2022 |
Est. completion date | September 1, 2025 |
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT followed by the administration of trastuzumab emtansine 24 hours after the SRT. The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure.
Status | Recruiting |
Enrollment | 58 |
Est. completion date | September 1, 2025 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients must be at least 18 years of age and able to give written informed consent and comply with study procedures; 2. Clinical diagnosis: breast cancer, metastatic form; 3. Oligo-metastatic disease as determined by standard of care diagnostics, limited to 5 total individual distant metastases, either in one organ or in 2-3 organ systems. Clustered lymph nodes that can be irradiated with curative intent in a single field are defined as single lesion; 4. Possibility of complete elimination of all foci; 5. HER2 expression level of 3+ points according to immunohistochemical analysis (IHC) and/or degree of amplification =2.0 according to the results of in situ hybridization (ISH); 6. Patients with stable metastatic brain foci for at least 4-6 weeks (according to MRI); 7. Patients with HER2+ inoperable locally advanced or metastatic breast cancer who previously received taxanes and trastuzumab; 8. ECOG 0-1 status; 9. Life expectancy of more than 6 months. Exclusion Criteria: 1. T-DM1 therapy in the medical history; 2. Autoimmune diseases in the medical history or treatment of exacerbations during the last three months; 3. Uncontrolled brain metastases and/or carcinomatous meningitis, causing neurological symptoms; 4. Primary multiple malignant tumors: other malignant neoplasms requiring active treatment; 5. Acute myocardial infarction, acute cerebrovascular accident, uncorrectable coagulopathy, decompensated concomitant pathology, infectious diseases in the active phase, ECOG status > 2; 6. Pregnancy, lactation. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | N.N. Petrov National Medical Research Center of Oncology | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
N.N. Petrov National Medical Research Center of Oncology |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) | Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by investigator assessment, per RECIST 1.1 | 3 month | |
Secondary | Progression free survival (PFS) | Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death. | 6 month | |
Secondary | Toxicity profile | The assessment of adverse events will be carried out according to the STS AE v.5.0 system. | 3 month | |
Secondary | Second co-primary outcome measure is quality of life | of Cancer (EORTC) Quality of Life Questionnaire for Cancer patients with 30 items (QLQ-C30) sum score | 3 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Not yet recruiting |
NCT06373497 -
Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography
|
Early Phase 1 | |
Recruiting |
NCT05377047 -
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
|
N/A | |
Recruiting |
NCT05223803 -
TERPS Trial for de Novo Oligometastic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04617457 -
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05679427 -
Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions
|
N/A | |
Recruiting |
NCT05277844 -
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT05951127 -
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
|
N/A | |
Active, not recruiting |
NCT05101824 -
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
|
N/A | |
Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
Recruiting |
NCT04748042 -
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
|
Phase 2 | |
Recruiting |
NCT06122480 -
Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT05784428 -
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
|
N/A | |
Completed |
NCT04593381 -
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer
|
N/A | |
Terminated |
NCT01345539 -
Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation
|
Phase 2 | |
Recruiting |
NCT05846646 -
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
|
Phase 2 | |
Recruiting |
NCT04973007 -
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
|
Phase 4 | |
Recruiting |
NCT06439888 -
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05917431 -
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
|
Phase 2 |